Dyax Announces Antibody Discovery Collaboration with Biogen Idec

11-Nov-2004

Dyax Corp. today announced a research collaboration to provide Biogen Idec with access to Dyax's fully human antibody libraries for the purpose of identification and characterization of therapeutic and/or diagnostic antibodies against up to thirty Biogen Idec protein targets per year. Under the terms of the agreement, Biogen Idec is providing research funding to Dyax for a minimum three-year period.

Biogen Idec retains rights to develop and commercialize antibodies identified in the collaboration, and Dyax will receive development milestone payments, as well as royalty payments upon successful commercialization by Biogen Idec of products based on antibodies identified by Dyax. Biogen Idec is focused on creating new standards of care in neurology, oncology and immunology.

"I'm very pleased to enter into this collaboration with Biogen Idec, and believe that Dyax's state-of-the-art libraries and high throughput screening technology will provide rapid results, to the benefit of both companies," remarked Henry E. Blair, Chairman, President and CEO of Dyax Corp.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous